TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
TCL Archive Letters To the Editor: NCI director Broder responds To Kopans On Mammography October 8, 1993
TCL Archive DCCR Advisory Committee Delays Planned Expansion Of Promising Community Clinical Oncology Program July 21, 1978
